Cargando…
Cell-mediated immunity to encephalitogenic factor (MMI test) in women with cervical dysplasia and carcinoma in situ: the effects of serum.
Lymphocyte sensitivity to encephalitogenic factor (EF) was measured with the macrophage migration inhibition (MMI) test in 60 women with dysplasia or carcinoma in situ of the cervix, in 10 women with invasive cervical carcinoma, and in 20 women with a variety of benign gynaecological conditions. Sig...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1978
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009746/ https://www.ncbi.nlm.nih.gov/pubmed/81675 |
_version_ | 1782136178671091712 |
---|---|
author | Flavell, D. J. Singer, A. Potter, C. W. |
author_facet | Flavell, D. J. Singer, A. Potter, C. W. |
author_sort | Flavell, D. J. |
collection | PubMed |
description | Lymphocyte sensitivity to encephalitogenic factor (EF) was measured with the macrophage migration inhibition (MMI) test in 60 women with dysplasia or carcinoma in situ of the cervix, in 10 women with invasive cervical carcinoma, and in 20 women with a variety of benign gynaecological conditions. Significant migration inhibition with EF (P less than 0.01) was seen with lymphocytes taken from 7/13 (54%) women with mild and/or moderate dysplasia, from 22/47 (47%) women with severe dysplasia and/or carcinoma in situ, from 6/10 (60%) women with invasive cervical carcinoma and from 3/20 (15%) women with benign gynaecological conditions. Autologous serum was seen to abrogate EF-mediated migration inhibition in 3/4 sensitized women with mild and/or moderate dysplasia, in 5/7 sensitized women with severe dysplasia and/or csrcinoma in situ and in 2/3 sensitized women with invasive cervical carcinoma. Autologous serum from 2 sensitized women with benign gynaecological conditions did not abrogate the response of their lymphocytes to EF. |
format | Text |
id | pubmed-2009746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1978 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20097462009-09-10 Cell-mediated immunity to encephalitogenic factor (MMI test) in women with cervical dysplasia and carcinoma in situ: the effects of serum. Flavell, D. J. Singer, A. Potter, C. W. Br J Cancer Research Article Lymphocyte sensitivity to encephalitogenic factor (EF) was measured with the macrophage migration inhibition (MMI) test in 60 women with dysplasia or carcinoma in situ of the cervix, in 10 women with invasive cervical carcinoma, and in 20 women with a variety of benign gynaecological conditions. Significant migration inhibition with EF (P less than 0.01) was seen with lymphocytes taken from 7/13 (54%) women with mild and/or moderate dysplasia, from 22/47 (47%) women with severe dysplasia and/or carcinoma in situ, from 6/10 (60%) women with invasive cervical carcinoma and from 3/20 (15%) women with benign gynaecological conditions. Autologous serum was seen to abrogate EF-mediated migration inhibition in 3/4 sensitized women with mild and/or moderate dysplasia, in 5/7 sensitized women with severe dysplasia and/or csrcinoma in situ and in 2/3 sensitized women with invasive cervical carcinoma. Autologous serum from 2 sensitized women with benign gynaecological conditions did not abrogate the response of their lymphocytes to EF. Nature Publishing Group 1978-09 /pmc/articles/PMC2009746/ /pubmed/81675 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Flavell, D. J. Singer, A. Potter, C. W. Cell-mediated immunity to encephalitogenic factor (MMI test) in women with cervical dysplasia and carcinoma in situ: the effects of serum. |
title | Cell-mediated immunity to encephalitogenic factor (MMI test) in women with cervical dysplasia and carcinoma in situ: the effects of serum. |
title_full | Cell-mediated immunity to encephalitogenic factor (MMI test) in women with cervical dysplasia and carcinoma in situ: the effects of serum. |
title_fullStr | Cell-mediated immunity to encephalitogenic factor (MMI test) in women with cervical dysplasia and carcinoma in situ: the effects of serum. |
title_full_unstemmed | Cell-mediated immunity to encephalitogenic factor (MMI test) in women with cervical dysplasia and carcinoma in situ: the effects of serum. |
title_short | Cell-mediated immunity to encephalitogenic factor (MMI test) in women with cervical dysplasia and carcinoma in situ: the effects of serum. |
title_sort | cell-mediated immunity to encephalitogenic factor (mmi test) in women with cervical dysplasia and carcinoma in situ: the effects of serum. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009746/ https://www.ncbi.nlm.nih.gov/pubmed/81675 |
work_keys_str_mv | AT flavelldj cellmediatedimmunitytoencephalitogenicfactormmitestinwomenwithcervicaldysplasiaandcarcinomainsitutheeffectsofserum AT singera cellmediatedimmunitytoencephalitogenicfactormmitestinwomenwithcervicaldysplasiaandcarcinomainsitutheeffectsofserum AT pottercw cellmediatedimmunitytoencephalitogenicfactormmitestinwomenwithcervicaldysplasiaandcarcinomainsitutheeffectsofserum |